AGP Picks
View all

New Review Confirms Modern Sacral Neuromodulation Delivers Highest Effectiveness & Most Favorable Safety Profile for UUI

News originally published by

EIN Presswire

Neuspera logo

CMS Finalizes CY 2027 OPPS Payment Parity with Legacy Systems for Neuspera SNM Under APC 5464

SAN JOSE, CA, UNITED STATES, November 16, 2026 /EINPresswire.com/ -- Neuspera® Medical, Inc., a leading developer of integrated technologies powering the future of neuromodulation, today announced the publication of a review article in the peer-reviewed journal Current Urology Reports that establishes a clear clinical hierarchy for implantable neuromodulation therapies for urinary urge incontinence (UUI). The paper concludes that modern sacral neuromodulation (SNM) systems, implanted with optimal techniques in appropriately selected patients, consistently deliver the highest effectiveness and the most favorable safety profile, while current implantable tibial neuromodulation (iTNM) outcomes remain comparable to legacy SNM and markedly lower than modern SNM.

The article, “Past, Present, and Future Implantable Neuromodulation Treatments for Management of Urinary Urge Incontinence (UUI): Implications for Clinical Effectiveness and Safety,” was authored by Steven Siegel, MD, Michael J. Ehlert, MD, Charles R. Powell, MD, and Melissa Kaufman, MD. The authors are experienced urologists with a history of publications in numerous peer-reviewed journals who have trained or influenced many physicians in the field. Dr. Siegel is Neuspera’s Chief Medical Officer.

Key findings from the review include:

• When combined with optimal lead placement techniques in properly selected patients, modern SNM systems (including the Neuspera® SNM System, Boston Scientific’s Axonics™, Medtronic’s InterStim™ Micro/X) demonstrate substantially higher responder rates than both previous-generation SNM and contemporary iTNM devices. [1] Based on the authors’ stratified analysis of contemporary data, responder rates ranged from 88–93% for ≥50% reduction in UUI episodes. [1]

• In the authors’ stratified analysis, reported iTNM responder rates (58%–78% across the eCoin®, Revi™, and Altaviva™ pivotal studies) were similar to those of earlier-generation SNM and did not overlap with the contemporary SNM range. [1]

• The authors note that pooling earlier- and contemporary-generation SNM studies, as done in a recent meta-analysis, may obscure generational differences in SNM outcomes. When the same literature is stratified by device era, technique, and patient selection, the contemporary SNM range (88–93%) is higher than the iTNM range (58–78%). [1]

• The Neuspera® SNM System is designed to deliver contemporary SNM performance in a fully percutaneous, externally powered design without an implanted battery.

“Simply stated, modern SNM is our best tool,” said Dr. Siegel. “When we properly distinguish contemporary devices, patient populations and techniques from earlier generations, the evidence shows a clear hierarchy. Modern SNM offers the highest effectiveness and the most favorable safety profile. Pooling older and newer data does not change what the contemporary literature actually shows. The Neuspera® system provides gold-standard efficacy while eliminating complications related to an implanted battery, including battery-replacement surgery and device-related adverse events.” [2], [3]

“The data do not support treating implantable tibial neuromodulation as equivalent to modern sacral neuromodulation,” said Melissa Kaufman, MD, co-author and Professor of Urology at Vanderbilt University Medical Center. “When contemporary SNM results are examined on their own, the difference in effectiveness is clear and consistent. That distinction matters for patients.”

“This review is the first of a series of analyses, including future meta-analyses, that will set the record straight on the true gold-standard efficacy of modern sacral neuromodulation,” said Dave Van Meter, CEO of Neuspera Medical. “We are strong supporters of more options for patients. But the evidence is clear that sacral neuromodulation is the most efficacious option. Patients deserve the therapy with the strongest demonstrated effectiveness and the fewest device-related burdens. Neuspera’s integrated design is the natural next step in the evolution of SNM: highly targeted, minimally invasive, and free of an implanted battery. We would like to thank the authors for their thorough and objective review and analysis of this data.”

The authors note that formal head-to-head trials will further refine comparisons, but the directional evidence from contemporary studies already supports modern SNM as the preferred option for most patients. They also highlight advantages of SNM for patients with dual urinary and bowel symptoms and the value of a percutaneous nerve evaluation (PNE) trial to avoid implanting non-responders. Neuspera partially funded the manuscript work.

Separately, the Centers for Medicare & Medicaid Services (CMS) has finalized assignment of the Neuspera® SNM System’s billing code (0786T) to Ambulatory Payment Classification (APC) 5464 in the Calendar Year 2027 Hospital Outpatient Prospective Payment System final rule. This confirms payment parity with other implantable neuromodulation therapies for UUI and supports broad access for Medicare beneficiaries.

About Neuspera Medical
Neuspera® Medical, Inc. is a leader in advanced, directionally adaptive energy systems that power tiny medical implants deep within the body. The company is introducing a new class of neurostimulation technology, starting with the first integrated sacral neuromodulation (iSNM) system approved by the FDA in June 2025 for urinary urge incontinence (UUI). Learn more at neuspera.com and on LinkedIn.

References
1. Siegel S, Ehlert MJ, Powell CR, Kaufman M. Past, present, and future implantable neuromodulation treatments for management of urinary urge incontinence (UUI): implications for clinical effectiveness and safety. Curr Urol Rep. 2026;27:61. doi:10.1007/s11934-026-01377-6.
2. Bretschneider CE, Sheyn D, Lanki N, Volpe L, Gupta A. Device-related reoperations 8 years following sacral neuromodulation implantation in older women. Int Urogynecol J. 2024;35(12):2349-2355. doi:10.1007/s00192-024-05891-4.
3. Padron O, et al. MP30-12 results of the SANS-UUI, phase II study: safety outcomes at 6 months for patients with OAB symptoms using Neuspera’s ultra-miniaturized system compared to the published standard of care. J Urol. 2025;213(5S):e1029. doi:10.1097/01.JU.0001110076.71872.1a.12.

media@capwellcomm.com
Neuspera® Medical, Inc.
Liz Wilkins
Visit us on social media:
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Golden State Newswire

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.